nodes	percent_of_prediction	percent_of_DWPC	metapath
Flurandrenolide—NR3C1—hematologic cancer	0.0893	1	CbGaD
Flurandrenolide—Betamethasone—hematologic cancer	0.0777	0.344	CrCtD
Flurandrenolide—Dexamethasone—hematologic cancer	0.0777	0.344	CrCtD
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Betamethasone—hematologic cancer	0.0726	0.209	CiPCiCtD
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Dexamethasone—hematologic cancer	0.0726	0.209	CiPCiCtD
Flurandrenolide—Prednisolone—hematologic cancer	0.0703	0.312	CrCtD
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Triamcinolone—hematologic cancer	0.0702	0.202	CiPCiCtD
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Prednisolone—hematologic cancer	0.0679	0.195	CiPCiCtD
Flurandrenolide—Corticosteroid Hormone Receptor Agonists—Prednisone—hematologic cancer	0.0642	0.185	CiPCiCtD
Flurandrenolide—SERPINA6—Triamcinolone—hematologic cancer	0.032	0.269	CbGbCtD
Flurandrenolide—SERPINA6—Prednisolone—hematologic cancer	0.0271	0.228	CbGbCtD
Flurandrenolide—NR3C1—Triamcinolone—hematologic cancer	0.015	0.126	CbGbCtD
Flurandrenolide—NR3C1—Betamethasone—hematologic cancer	0.0128	0.108	CbGbCtD
Flurandrenolide—NR3C1—Prednisolone—hematologic cancer	0.0127	0.106	CbGbCtD
Flurandrenolide—NR3C1—Prednisone—hematologic cancer	0.012	0.101	CbGbCtD
Flurandrenolide—NR3C1—Dexamethasone—hematologic cancer	0.00747	0.0627	CbGbCtD
Flurandrenolide—Ciclesonide—Prednisone—hematologic cancer	0.00262	0.0156	CrCrCtD
Flurandrenolide—Ciclesonide—Prednisolone—hematologic cancer	0.00256	0.0152	CrCrCtD
Flurandrenolide—Medrysone—Prednisolone—hematologic cancer	0.00246	0.0146	CrCrCtD
Flurandrenolide—Clocortolone—Dexamethasone—hematologic cancer	0.00223	0.0132	CrCrCtD
Flurandrenolide—Fluocinonide—Betamethasone—hematologic cancer	0.00223	0.0132	CrCrCtD
Flurandrenolide—Clocortolone—Betamethasone—hematologic cancer	0.00223	0.0132	CrCrCtD
Flurandrenolide—Fluocinonide—Dexamethasone—hematologic cancer	0.00223	0.0132	CrCrCtD
Flurandrenolide—Hydrocortamate—Prednisone—hematologic cancer	0.00219	0.013	CrCrCtD
Flurandrenolide—Fluocinonide—Triamcinolone—hematologic cancer	0.00217	0.0129	CrCrCtD
Flurandrenolide—Clocortolone—Triamcinolone—hematologic cancer	0.00217	0.0129	CrCrCtD
Flurandrenolide—Fluocortolone—Dexamethasone—hematologic cancer	0.00216	0.0128	CrCrCtD
Flurandrenolide—Fluocortolone—Betamethasone—hematologic cancer	0.00216	0.0128	CrCrCtD
Flurandrenolide—Hydrocortamate—Prednisolone—hematologic cancer	0.00214	0.0127	CrCrCtD
Flurandrenolide—Fluocortolone—Triamcinolone—hematologic cancer	0.00211	0.0125	CrCrCtD
Flurandrenolide—Fluocinolone Acetonide—Dexamethasone—hematologic cancer	0.0021	0.0125	CrCrCtD
Flurandrenolide—Alclometasone—Dexamethasone—hematologic cancer	0.0021	0.0125	CrCrCtD
Flurandrenolide—Alclometasone—Betamethasone—hematologic cancer	0.0021	0.0125	CrCrCtD
Flurandrenolide—Fluocinolone Acetonide—Betamethasone—hematologic cancer	0.0021	0.0125	CrCrCtD
Flurandrenolide—Alclometasone—Triamcinolone—hematologic cancer	0.00205	0.0122	CrCrCtD
Flurandrenolide—Fluocinolone Acetonide—Triamcinolone—hematologic cancer	0.00205	0.0122	CrCrCtD
Flurandrenolide—Budesonide—Betamethasone—hematologic cancer	0.00205	0.0121	CrCrCtD
Flurandrenolide—Amcinonide—Betamethasone—hematologic cancer	0.00205	0.0121	CrCrCtD
Flurandrenolide—Amcinonide—Dexamethasone—hematologic cancer	0.00205	0.0121	CrCrCtD
Flurandrenolide—Budesonide—Dexamethasone—hematologic cancer	0.00205	0.0121	CrCrCtD
Flurandrenolide—Clocortolone—Prednisolone—hematologic cancer	0.00201	0.012	CrCrCtD
Flurandrenolide—Fluocortolone—Prednisone—hematologic cancer	0.002	0.0119	CrCrCtD
Flurandrenolide—Amcinonide—Triamcinolone—hematologic cancer	0.002	0.0119	CrCrCtD
Flurandrenolide—Budesonide—Triamcinolone—hematologic cancer	0.002	0.0119	CrCrCtD
Flurandrenolide—Diflorasone—Dexamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Desonide—Betamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Flunisolide—Betamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Desonide—Dexamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Flunisolide—Dexamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Diflorasone—Betamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Fludrocortisone—Betamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Fludrocortisone—Dexamethasone—hematologic cancer	0.00199	0.0118	CrCrCtD
Flurandrenolide—Fluocortolone—Prednisolone—hematologic cancer	0.00196	0.0116	CrCrCtD
Flurandrenolide—Alclometasone—Prednisone—hematologic cancer	0.00195	0.0116	CrCrCtD
Flurandrenolide—Diflorasone—Triamcinolone—hematologic cancer	0.00195	0.0116	CrCrCtD
Flurandrenolide—Fludrocortisone—Triamcinolone—hematologic cancer	0.00195	0.0116	CrCrCtD
Flurandrenolide—Flunisolide—Triamcinolone—hematologic cancer	0.00195	0.0116	CrCrCtD
Flurandrenolide—Desonide—Triamcinolone—hematologic cancer	0.00195	0.0116	CrCrCtD
Flurandrenolide—Paramethasone—Dexamethasone—hematologic cancer	0.00194	0.0115	CrCrCtD
Flurandrenolide—Paramethasone—Betamethasone—hematologic cancer	0.00194	0.0115	CrCrCtD
Flurandrenolide—Alclometasone—Prednisolone—hematologic cancer	0.0019	0.0113	CrCrCtD
Flurandrenolide—Fluocinolone Acetonide—Prednisolone—hematologic cancer	0.0019	0.0113	CrCrCtD
Flurandrenolide—Paramethasone—Triamcinolone—hematologic cancer	0.0019	0.0113	CrCrCtD
Flurandrenolide—Budesonide—Prednisone—hematologic cancer	0.0019	0.0113	CrCrCtD
Flurandrenolide—Amcinonide—Prednisone—hematologic cancer	0.0019	0.0113	CrCrCtD
Flurandrenolide—Budesonide—Prednisolone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Amcinonide—Prednisolone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Desonide—Prednisone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Diflorasone—Prednisone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Fludrocortisone—Prednisone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Flunisolide—Prednisone—hematologic cancer	0.00185	0.011	CrCrCtD
Flurandrenolide—Rimexolone—Dexamethasone—hematologic cancer	0.00181	0.0107	CrCrCtD
Flurandrenolide—Rimexolone—Betamethasone—hematologic cancer	0.00181	0.0107	CrCrCtD
Flurandrenolide—Betamethasone—Dexamethasone—hematologic cancer	0.00181	0.0107	CrCrCtD
Flurandrenolide—Dexamethasone—Betamethasone—hematologic cancer	0.00181	0.0107	CrCrCtD
Flurandrenolide—Diflorasone—Prednisolone—hematologic cancer	0.0018	0.0107	CrCrCtD
Flurandrenolide—Fludrocortisone—Prednisolone—hematologic cancer	0.0018	0.0107	CrCrCtD
Flurandrenolide—Flunisolide—Prednisolone—hematologic cancer	0.0018	0.0107	CrCrCtD
Flurandrenolide—Desonide—Prednisolone—hematologic cancer	0.0018	0.0107	CrCrCtD
Flurandrenolide—Paramethasone—Prednisone—hematologic cancer	0.0018	0.0107	CrCrCtD
Flurandrenolide—Dexamethasone—Triamcinolone—hematologic cancer	0.00177	0.0105	CrCrCtD
Flurandrenolide—Rimexolone—Triamcinolone—hematologic cancer	0.00177	0.0105	CrCrCtD
Flurandrenolide—Betamethasone—Triamcinolone—hematologic cancer	0.00177	0.0105	CrCrCtD
Flurandrenolide—Paramethasone—Prednisolone—hematologic cancer	0.00176	0.0104	CrCrCtD
Flurandrenolide—Methylprednisolone—Dexamethasone—hematologic cancer	0.00173	0.0103	CrCrCtD
Flurandrenolide—Methylprednisolone—Betamethasone—hematologic cancer	0.00173	0.0103	CrCrCtD
Flurandrenolide—Prednisolone—Betamethasone—hematologic cancer	0.00169	0.01	CrCrCtD
Flurandrenolide—Prednisolone—Dexamethasone—hematologic cancer	0.00169	0.01	CrCrCtD
Flurandrenolide—Methylprednisolone—Triamcinolone—hematologic cancer	0.00169	0.01	CrCrCtD
Flurandrenolide—Rimexolone—Prednisone—hematologic cancer	0.00168	0.00995	CrCrCtD
Flurandrenolide—Dexamethasone—Prednisone—hematologic cancer	0.00168	0.00995	CrCrCtD
Flurandrenolide—Betamethasone—Prednisone—hematologic cancer	0.00168	0.00995	CrCrCtD
Flurandrenolide—Prednisolone—Triamcinolone—hematologic cancer	0.00165	0.00982	CrCrCtD
Flurandrenolide—Betamethasone—Prednisolone—hematologic cancer	0.00164	0.00971	CrCrCtD
Flurandrenolide—Dexamethasone—Prednisolone—hematologic cancer	0.00164	0.00971	CrCrCtD
Flurandrenolide—Rimexolone—Prednisolone—hematologic cancer	0.00164	0.00971	CrCrCtD
Flurandrenolide—Hydrocortisone—Dexamethasone—hematologic cancer	0.00162	0.00964	CrCrCtD
Flurandrenolide—Hydrocortisone—Betamethasone—hematologic cancer	0.00162	0.00964	CrCrCtD
Flurandrenolide—Methylprednisolone—Prednisone—hematologic cancer	0.0016	0.00952	CrCrCtD
Flurandrenolide—Hydrocortisone—Triamcinolone—hematologic cancer	0.00159	0.00942	CrCrCtD
Flurandrenolide—Prednisolone—Prednisone—hematologic cancer	0.00157	0.00932	CrCrCtD
Flurandrenolide—Methylprednisolone—Prednisolone—hematologic cancer	0.00157	0.00929	CrCrCtD
Flurandrenolide—Hydrocortisone—Prednisone—hematologic cancer	0.00151	0.00894	CrCrCtD
Flurandrenolide—Hydrocortisone—Prednisolone—hematologic cancer	0.00147	0.00873	CrCrCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—RFXANK—hematologic cancer	0.000502	0.0406	CbGpPWpGaD
Flurandrenolide—Allergic contact dermatitis—Dexamethasone—hematologic cancer	0.000257	0.00731	CcSEcCtD
Flurandrenolide—Leukoderma—Prednisolone—hematologic cancer	0.000254	0.0072	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CRY2—hematologic cancer	0.000251	0.0203	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PER2—hematologic cancer	0.000251	0.0203	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CRY1—hematologic cancer	0.000251	0.0203	CbGpPWpGaD
Flurandrenolide—SERPINA6—hematopoietic system—hematologic cancer	0.00025	0.204	CbGeAlD
Flurandrenolide—Skin striae—Prednisone—hematologic cancer	0.000246	0.007	CcSEcCtD
Flurandrenolide—Skin discolouration—Dasatinib—hematologic cancer	0.000245	0.00696	CcSEcCtD
Flurandrenolide—Hypertrichosis—Dexamethasone—hematologic cancer	0.000237	0.00672	CcSEcCtD
Flurandrenolide—Hypertrichosis—Betamethasone—hematologic cancer	0.000237	0.00672	CcSEcCtD
Flurandrenolide—Leukoderma—Triamcinolone—hematologic cancer	0.000233	0.00662	CcSEcCtD
Flurandrenolide—Skin discolouration—Nilotinib—hematologic cancer	0.000227	0.00643	CcSEcCtD
Flurandrenolide—Folliculitis—Alitretinoin—hematologic cancer	0.000223	0.00633	CcSEcCtD
Flurandrenolide—Dermatitis contact—Bexarotene—hematologic cancer	0.000219	0.00622	CcSEcCtD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—CEBPD—hematologic cancer	0.000218	0.0176	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—CEBPA—hematologic cancer	0.000218	0.0176	CbGpPWpGaD
Flurandrenolide—Leukoderma—Betamethasone—hematologic cancer	0.000212	0.00601	CcSEcCtD
Flurandrenolide—Leukoderma—Dexamethasone—hematologic cancer	0.000212	0.00601	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—HDAC11—hematologic cancer	0.000209	0.0169	CbGpPWpGaD
Flurandrenolide—Secondary infection—Epirubicin—hematologic cancer	0.000208	0.00592	CcSEcCtD
Flurandrenolide—Eruption—Gemcitabine—hematologic cancer	0.000208	0.00591	CcSEcCtD
Flurandrenolide—Hypertrichosis—Prednisone—hematologic cancer	0.000206	0.00585	CcSEcCtD
Flurandrenolide—Skin discolouration—Lenalidomide—hematologic cancer	0.000196	0.00558	CcSEcCtD
Flurandrenolide—Secondary infection—Doxorubicin—hematologic cancer	0.000193	0.00548	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—GATA2—hematologic cancer	0.000193	0.0156	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—PER1—hematologic cancer	0.00019	0.0153	CbGpPWpGaD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—HDAC10—hematologic cancer	0.000186	0.015	CbGpPWpGaD
Flurandrenolide—Leukoderma—Prednisone—hematologic cancer	0.000184	0.00523	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—PER2—hematologic cancer	0.000183	0.0147	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—CRY1—hematologic cancer	0.000183	0.0147	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—CRY2—hematologic cancer	0.000183	0.0147	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Bortezomib—hematologic cancer	0.000181	0.00513	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—BCL6—hematologic cancer	0.000175	0.0141	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Thiotepa—hematologic cancer	0.000168	0.00479	CcSEcCtD
Flurandrenolide—Infection—Ruxolitinib—hematologic cancer	0.000166	0.00473	CcSEcCtD
Flurandrenolide—SERPINA6—blood—hematologic cancer	0.000166	0.135	CbGeAlD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—GATA1—hematologic cancer	0.000166	0.0134	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Thalidomide—hematologic cancer	0.000163	0.00463	CcSEcCtD
Flurandrenolide—SERPINA6—bone marrow—hematologic cancer	0.00016	0.131	CbGeAlD
Flurandrenolide—Folliculitis—Triamcinolone—hematologic cancer	0.000158	0.00448	CcSEcCtD
Flurandrenolide—Skin discolouration—Alitretinoin—hematologic cancer	0.000155	0.0044	CcSEcCtD
Flurandrenolide—Leukoderma—Methotrexate—hematologic cancer	0.000154	0.00437	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptors—RARA—hematologic cancer	0.000152	0.0122	CbGpPWpGaD
Flurandrenolide—Dermatitis contact—Thiotepa—hematologic cancer	0.00015	0.00427	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—GATA2—hematologic cancer	0.000148	0.0119	CbGpPWpGaD
Flurandrenolide—SERPINA6—lung—hematologic cancer	0.000145	0.119	CbGeAlD
Flurandrenolide—Leukoderma—Epirubicin—hematologic cancer	0.000144	0.00409	CcSEcCtD
Flurandrenolide—Folliculitis—Dexamethasone—hematologic cancer	0.000143	0.00407	CcSEcCtD
Flurandrenolide—Folliculitis—Betamethasone—hematologic cancer	0.000143	0.00407	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—PBX1—hematologic cancer	0.000143	0.0115	CbGpPWpGaD
Flurandrenolide—Infection—Vorinostat—hematologic cancer	0.000141	0.004	CcSEcCtD
Flurandrenolide—Dermatitis contact—Alitretinoin—hematologic cancer	0.000138	0.00393	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—PER1—hematologic cancer	0.000138	0.0112	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—DUSP5—hematologic cancer	0.000137	0.0111	CbGpPWpGaD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—TUBB2A—hematologic cancer	0.000136	0.011	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—ARNTL—hematologic cancer	0.000135	0.0109	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CBFB—hematologic cancer	0.000134	0.0108	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MAF—hematologic cancer	0.000134	0.0108	CbGpPWpGaD
Flurandrenolide—Leukoderma—Doxorubicin—hematologic cancer	0.000133	0.00379	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—NCOR2—hematologic cancer	0.000127	0.0103	CbGpPWpGaD
Flurandrenolide—Infection—Lomustine—hematologic cancer	0.000126	0.00358	CcSEcCtD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—CEBPD—hematologic cancer	0.000125	0.0101	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—CEBPA—hematologic cancer	0.000125	0.0101	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—TLX3—hematologic cancer	0.000123	0.00994	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Etoposide—hematologic cancer	0.000121	0.00344	CcSEcCtD
Flurandrenolide—Infection—Mechlorethamine—hematologic cancer	0.000121	0.00343	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—SUMO1—hematologic cancer	0.00012	0.00968	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—RARA—hematologic cancer	0.00012	0.00968	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CBFB—hematologic cancer	0.000119	0.00964	CbGpPWpGaD
Flurandrenolide—Pruritus—Ruxolitinib—hematologic cancer	0.000119	0.00337	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—SPI1—hematologic cancer	0.000118	0.00955	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—GATA2—hematologic cancer	0.000118	0.00954	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—EOMES—hematologic cancer	0.000117	0.00943	CbGpPWpGaD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—HDAC9—hematologic cancer	0.000116	0.00938	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—TCF3—hematologic cancer	0.000114	0.0092	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—NR0B2—hematologic cancer	0.000111	0.009	CbGpPWpGaD
Flurandrenolide—NR3C1—hematopoietic system—hematologic cancer	0.00011	0.0895	CbGeAlD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—CEBPA—hematologic cancer	0.000108	0.00872	CbGpPWpGaD
Flurandrenolide—Eruption—Methotrexate—hematologic cancer	0.000106	0.00302	CcSEcCtD
Flurandrenolide—Folliculitis—Methotrexate—hematologic cancer	0.000104	0.00296	CcSEcCtD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—NF1—hematologic cancer	0.000102	0.00825	CbGpPWpGaD
Flurandrenolide—Infection—Nelarabine—hematologic cancer	0.000102	0.00289	CcSEcCtD
Flurandrenolide—Pruritus—Vorinostat—hematologic cancer	0.0001	0.00285	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—NUP214—hematologic cancer	9.97e-05	0.00806	CbGpPWpGaD
Flurandrenolide—Eruption—Epirubicin—hematologic cancer	9.96e-05	0.00283	CcSEcCtD
Flurandrenolide—Infection—Methoxsalen—hematologic cancer	9.95e-05	0.00283	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—ARNTL—hematologic cancer	9.86e-05	0.00796	CbGpPWpGaD
Flurandrenolide—Dermatitis contact—Triamcinolone—hematologic cancer	9.8e-05	0.00278	CcSEcCtD
Flurandrenolide—Folliculitis—Epirubicin—hematologic cancer	9.75e-05	0.00277	CcSEcCtD
Flurandrenolide—Infection—Clofarabine—hematologic cancer	9.54e-05	0.00271	CcSEcCtD
Flurandrenolide—Infection—Daunorubicin—hematologic cancer	9.54e-05	0.00271	CcSEcCtD
Flurandrenolide—Infection—Anagrelide—hematologic cancer	9.49e-05	0.0027	CcSEcCtD
Flurandrenolide—Infection—Pentostatin—hematologic cancer	9.49e-05	0.0027	CcSEcCtD
Flurandrenolide—Eruption—Doxorubicin—hematologic cancer	9.22e-05	0.00262	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—EBF1—hematologic cancer	9.17e-05	0.00741	CbGpPWpGaD
Flurandrenolide—Infection—Idarubicin—hematologic cancer	9.16e-05	0.0026	CcSEcCtD
Flurandrenolide—Folliculitis—Doxorubicin—hematologic cancer	9.02e-05	0.00256	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—LEF1—hematologic cancer	9e-05	0.00727	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Mechlorethamine—hematologic cancer	8.96e-05	0.00254	CcSEcCtD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—FOXO1—hematologic cancer	8.93e-05	0.00721	CbGpPWpGaD
Flurandrenolide—Infection—Teniposide—hematologic cancer	8.91e-05	0.00253	CcSEcCtD
Flurandrenolide—Dermatitis contact—Dexamethasone—hematologic cancer	8.89e-05	0.00253	CcSEcCtD
Flurandrenolide—Dermatitis contact—Betamethasone—hematologic cancer	8.89e-05	0.00253	CcSEcCtD
Flurandrenolide—Pruritus—Mechlorethamine—hematologic cancer	8.6e-05	0.00244	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—PBX1—hematologic cancer	8.53e-05	0.00689	CbGpPWpGaD
Flurandrenolide—NR3C1—gonad—hematologic cancer	8.33e-05	0.068	CbGeAlD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—hematologic cancer	8.27e-05	0.00668	CbGpPWpGaD
Flurandrenolide—Infection—Busulfan—hematologic cancer	8.25e-05	0.00234	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—SGK1—hematologic cancer	8.19e-05	0.00662	CbGpPWpGaD
Flurandrenolide—Infection—Procarbazine—hematologic cancer	8.01e-05	0.00227	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—REL—hematologic cancer	7.93e-05	0.0064	CbGpPWpGaD
Flurandrenolide—Infection—Dasatinib—hematologic cancer	7.85e-05	0.00223	CcSEcCtD
Flurandrenolide—Infection—Bexarotene—hematologic cancer	7.85e-05	0.00223	CcSEcCtD
Flurandrenolide—Infection—Fludarabine—hematologic cancer	7.83e-05	0.00222	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—ID3—hematologic cancer	7.8e-05	0.0063	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—hematologic cancer	7.74e-05	0.00626	CbGpPWpGaD
Flurandrenolide—Rash—Mechlorethamine—hematologic cancer	7.67e-05	0.00218	CcSEcCtD
Flurandrenolide—Dermatitis—Mechlorethamine—hematologic cancer	7.66e-05	0.00218	CcSEcCtD
Flurandrenolide—Infection—Chlorambucil—hematologic cancer	7.42e-05	0.00211	CcSEcCtD
Flurandrenolide—Hypersensitivity—Methoxsalen—hematologic cancer	7.38e-05	0.0021	CcSEcCtD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—CREB1—hematologic cancer	7.28e-05	0.00588	CbGpPWpGaD
Flurandrenolide—NR3C1—blood—hematologic cancer	7.26e-05	0.0593	CbGeAlD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—HSP90AA1—hematologic cancer	7.26e-05	0.00587	CbGpPWpGaD
Flurandrenolide—Infection—Nilotinib—hematologic cancer	7.25e-05	0.00206	CcSEcCtD
Flurandrenolide—Skin discolouration—Methotrexate—hematologic cancer	7.25e-05	0.00206	CcSEcCtD
Flurandrenolide—Infection—Imatinib—hematologic cancer	7.21e-05	0.00205	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—GATA2—hematologic cancer	7.2e-05	0.00581	CbGpPWpGaD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—hematologic cancer	7.19e-05	0.00581	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Mercaptopurine—hematologic cancer	7.17e-05	0.00204	CcSEcCtD
Flurandrenolide—Pruritus—Methoxsalen—hematologic cancer	7.09e-05	0.00201	CcSEcCtD
Flurandrenolide—Infection—Cladribine—hematologic cancer	7.09e-05	0.00201	CcSEcCtD
Flurandrenolide—Hypersensitivity—Daunorubicin—hematologic cancer	7.07e-05	0.00201	CcSEcCtD
Flurandrenolide—Hypersensitivity—Clofarabine—hematologic cancer	7.07e-05	0.00201	CcSEcCtD
Flurandrenolide—Hypersensitivity—Pentostatin—hematologic cancer	7.04e-05	0.002	CcSEcCtD
Flurandrenolide—NR3C1—bone marrow—hematologic cancer	7.03e-05	0.0574	CbGeAlD
Flurandrenolide—NR3C1—AP-1 transcription factor network—JUND—hematologic cancer	6.91e-05	0.00558	CbGpPWpGaD
Flurandrenolide—Pruritus—Clofarabine—hematologic cancer	6.79e-05	0.00193	CcSEcCtD
Flurandrenolide—Pruritus—Daunorubicin—hematologic cancer	6.79e-05	0.00193	CcSEcCtD
Flurandrenolide—Hypersensitivity—Idarubicin—hematologic cancer	6.79e-05	0.00193	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MYB—hematologic cancer	6.78e-05	0.00548	CbGpPWpGaD
Flurandrenolide—Skin discolouration—Epirubicin—hematologic cancer	6.78e-05	0.00193	CcSEcCtD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAP2K1—hematologic cancer	6.77e-05	0.00547	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptors—AR—hematologic cancer	6.77e-05	0.00547	CbGpPWpGaD
Flurandrenolide—Pruritus—Anagrelide—hematologic cancer	6.76e-05	0.00192	CcSEcCtD
Flurandrenolide—Pruritus—Pentostatin—hematologic cancer	6.76e-05	0.00192	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—TCF3—hematologic cancer	6.74e-05	0.00545	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Teniposide—hematologic cancer	6.6e-05	0.00188	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—DKK1—hematologic cancer	6.54e-05	0.00529	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—hematologic cancer	6.54e-05	0.00528	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—CREB1—hematologic cancer	6.48e-05	0.00523	CbGpPWpGaD
Flurandrenolide—Infection—Melphalan—hematologic cancer	6.46e-05	0.00184	CcSEcCtD
Flurandrenolide—NR3C1—lung—hematologic cancer	6.37e-05	0.052	CbGeAlD
Flurandrenolide—Pruritus—Teniposide—hematologic cancer	6.34e-05	0.0018	CcSEcCtD
Flurandrenolide—Rash—Methoxsalen—hematologic cancer	6.32e-05	0.00179	CcSEcCtD
Flurandrenolide—Dermatitis—Methoxsalen—hematologic cancer	6.31e-05	0.00179	CcSEcCtD
Flurandrenolide—Infection—Lenalidomide—hematologic cancer	6.28e-05	0.00179	CcSEcCtD
Flurandrenolide—Skin discolouration—Doxorubicin—hematologic cancer	6.28e-05	0.00178	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—GATA2—hematologic cancer	6.22e-05	0.00503	CbGpPWpGaD
Flurandrenolide—Infection—Hydroxyurea—hematologic cancer	6.2e-05	0.00176	CcSEcCtD
Flurandrenolide—Rash—Mercaptopurine—hematologic cancer	6.14e-05	0.00174	CcSEcCtD
Flurandrenolide—Dermatitis—Mercaptopurine—hematologic cancer	6.13e-05	0.00174	CcSEcCtD
Flurandrenolide—Hypersensitivity—Busulfan—hematologic cancer	6.12e-05	0.00174	CcSEcCtD
Flurandrenolide—Clocortolone—NR3C1—hematologic cancer	6.06e-05	0.0562	CrCbGaD
Flurandrenolide—Dermatitis contact—Epirubicin—hematologic cancer	6.05e-05	0.00172	CcSEcCtD
Flurandrenolide—Rash—Clofarabine—hematologic cancer	6.05e-05	0.00172	CcSEcCtD
Flurandrenolide—Rash—Daunorubicin—hematologic cancer	6.05e-05	0.00172	CcSEcCtD
Flurandrenolide—Dermatitis—Clofarabine—hematologic cancer	6.05e-05	0.00172	CcSEcCtD
Flurandrenolide—Dermatitis—Daunorubicin—hematologic cancer	6.05e-05	0.00172	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—hematologic cancer	6.05e-05	0.00488	CbGpPWpGaD
Flurandrenolide—Rash—Anagrelide—hematologic cancer	6.03e-05	0.00171	CcSEcCtD
Flurandrenolide—Rash—Pentostatin—hematologic cancer	6.03e-05	0.00171	CcSEcCtD
Flurandrenolide—Dermatitis—Pentostatin—hematologic cancer	6.02e-05	0.00171	CcSEcCtD
Flurandrenolide—Dermatitis—Anagrelide—hematologic cancer	6.02e-05	0.00171	CcSEcCtD
Flurandrenolide—NR3C1—testis—hematologic cancer	6.01e-05	0.049	CbGeAlD
Flurandrenolide—Hypersensitivity—Procarbazine—hematologic cancer	5.94e-05	0.00169	CcSEcCtD
Flurandrenolide—Pruritus—Busulfan—hematologic cancer	5.88e-05	0.00167	CcSEcCtD
Flurandrenolide—Hypersensitivity—Bexarotene—hematologic cancer	5.82e-05	0.00165	CcSEcCtD
Flurandrenolide—Hypersensitivity—Dasatinib—hematologic cancer	5.82e-05	0.00165	CcSEcCtD
Flurandrenolide—Rash—Idarubicin—hematologic cancer	5.81e-05	0.00165	CcSEcCtD
Flurandrenolide—Dermatitis—Idarubicin—hematologic cancer	5.81e-05	0.00165	CcSEcCtD
Flurandrenolide—Hypersensitivity—Fludarabine—hematologic cancer	5.8e-05	0.00165	CcSEcCtD
Flurandrenolide—Drospirenone—AR—hematologic cancer	5.78e-05	0.0536	CrCbGaD
Flurandrenolide—Infection—Bortezomib—hematologic cancer	5.78e-05	0.00164	CcSEcCtD
Flurandrenolide—Infection—Bleomycin—hematologic cancer	5.74e-05	0.00163	CcSEcCtD
Flurandrenolide—Desonide—NR3C1—hematologic cancer	5.73e-05	0.0532	CrCbGaD
Flurandrenolide—Diflorasone—NR3C1—hematologic cancer	5.73e-05	0.0532	CrCbGaD
Flurandrenolide—Pruritus—Procarbazine—hematologic cancer	5.7e-05	0.00162	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—PTHLH—hematologic cancer	5.7e-05	0.00461	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—RARA—hematologic cancer	5.67e-05	0.00458	CbGpPWpGaD
Flurandrenolide—Rash—Teniposide—hematologic cancer	5.65e-05	0.00161	CcSEcCtD
Flurandrenolide—Dermatitis—Teniposide—hematologic cancer	5.65e-05	0.0016	CcSEcCtD
Flurandrenolide—Infection—Vinorelbine—hematologic cancer	5.65e-05	0.0016	CcSEcCtD
Flurandrenolide—Dermatitis contact—Doxorubicin—hematologic cancer	5.6e-05	0.00159	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—STAT5B—hematologic cancer	5.59e-05	0.00452	CbGpPWpGaD
Flurandrenolide—Pruritus—Bexarotene—hematologic cancer	5.59e-05	0.00159	CcSEcCtD
Flurandrenolide—Pruritus—Dasatinib—hematologic cancer	5.59e-05	0.00159	CcSEcCtD
Flurandrenolide—Pruritus—Fludarabine—hematologic cancer	5.57e-05	0.00158	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—HSP90AA1—hematologic cancer	5.56e-05	0.00449	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Chlorambucil—hematologic cancer	5.5e-05	0.00156	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—RET—hematologic cancer	5.49e-05	0.00444	CbGpPWpGaD
Flurandrenolide—Fludrocortisone—AR—hematologic cancer	5.45e-05	0.0505	CrCbGaD
Flurandrenolide—Infection—Thiotepa—hematologic cancer	5.39e-05	0.00153	CcSEcCtD
Flurandrenolide—Hypersensitivity—Nilotinib—hematologic cancer	5.38e-05	0.00153	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—AR—hematologic cancer	5.35e-05	0.00432	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Imatinib—hematologic cancer	5.35e-05	0.00152	CcSEcCtD
Flurandrenolide—Pruritus—Chlorambucil—hematologic cancer	5.28e-05	0.0015	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—CEBPA—hematologic cancer	5.27e-05	0.00426	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—CEBPD—hematologic cancer	5.27e-05	0.00426	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Cladribine—hematologic cancer	5.25e-05	0.00149	CcSEcCtD
Flurandrenolide—Rash—Busulfan—hematologic cancer	5.24e-05	0.00149	CcSEcCtD
Flurandrenolide—Dermatitis—Busulfan—hematologic cancer	5.23e-05	0.00149	CcSEcCtD
Flurandrenolide—Infection—Thalidomide—hematologic cancer	5.22e-05	0.00148	CcSEcCtD
Flurandrenolide—NR3C1—Generic Transcription Pathway—ZNF552—hematologic cancer	5.2e-05	0.0042	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—EZH2—hematologic cancer	5.19e-05	0.00419	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—AR—hematologic cancer	5.19e-05	0.00419	CbGpPWpGaD
Flurandrenolide—Pruritus—Nilotinib—hematologic cancer	5.16e-05	0.00147	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—SMARCA4—hematologic cancer	5.14e-05	0.00416	CbGpPWpGaD
Flurandrenolide—Pruritus—Imatinib—hematologic cancer	5.14e-05	0.00146	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL13—hematologic cancer	5.11e-05	0.00413	CbGpPWpGaD
Flurandrenolide—Rash—Procarbazine—hematologic cancer	5.08e-05	0.00144	CcSEcCtD
Flurandrenolide—Dermatitis—Procarbazine—hematologic cancer	5.08e-05	0.00144	CcSEcCtD
Flurandrenolide—Medrysone—NR3C1—hematologic cancer	5.08e-05	0.0471	CrCbGaD
Flurandrenolide—Pruritus—Cladribine—hematologic cancer	5.05e-05	0.00143	CcSEcCtD
Flurandrenolide—Hypersensitivity—Vinblastine—hematologic cancer	5.04e-05	0.00143	CcSEcCtD
Flurandrenolide—Infection—Carmustine—hematologic cancer	5.01e-05	0.00142	CcSEcCtD
Flurandrenolide—Rash—Bexarotene—hematologic cancer	4.98e-05	0.00142	CcSEcCtD
Flurandrenolide—Rash—Dasatinib—hematologic cancer	4.98e-05	0.00142	CcSEcCtD
Flurandrenolide—Dermatitis—Bexarotene—hematologic cancer	4.98e-05	0.00141	CcSEcCtD
Flurandrenolide—Dermatitis—Dasatinib—hematologic cancer	4.98e-05	0.00141	CcSEcCtD
Flurandrenolide—Rash—Fludarabine—hematologic cancer	4.97e-05	0.00141	CcSEcCtD
Flurandrenolide—Dermatitis—Fludarabine—hematologic cancer	4.96e-05	0.00141	CcSEcCtD
Flurandrenolide—Infection—Alitretinoin—hematologic cancer	4.96e-05	0.00141	CcSEcCtD
Flurandrenolide—Infection—Ifosfamide—hematologic cancer	4.9e-05	0.00139	CcSEcCtD
Flurandrenolide—Hypersensitivity—Melphalan—hematologic cancer	4.79e-05	0.00136	CcSEcCtD
Flurandrenolide—Infection—Vincristine—hematologic cancer	4.78e-05	0.00136	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—NCOR2—hematologic cancer	4.76e-05	0.00384	CbGpPWpGaD
Flurandrenolide—Hydrocortamate—NR3C1—hematologic cancer	4.73e-05	0.0439	CrCbGaD
Flurandrenolide—Hypersensitivity—Lenalidomide—hematologic cancer	4.66e-05	0.00132	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—GATA3—hematologic cancer	4.66e-05	0.00376	CbGpPWpGaD
Flurandrenolide—Infection—Mitoxantrone—hematologic cancer	4.66e-05	0.00132	CcSEcCtD
Flurandrenolide—Infection—Irinotecan—hematologic cancer	4.66e-05	0.00132	CcSEcCtD
Flurandrenolide—NR3C1—Signaling events mediated by HDAC Class II—ESR1—hematologic cancer	4.65e-05	0.00376	CbGpPWpGaD
Flurandrenolide—NR3C1—Nuclear Receptors—ESR1—hematologic cancer	4.65e-05	0.00376	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—GATA3—hematologic cancer	4.61e-05	0.00373	CbGpPWpGaD
Flurandrenolide—Pruritus—Melphalan—hematologic cancer	4.6e-05	0.00131	CcSEcCtD
Flurandrenolide—Rash—Nilotinib—hematologic cancer	4.6e-05	0.00131	CcSEcCtD
Flurandrenolide—Dermatitis—Nilotinib—hematologic cancer	4.6e-05	0.00131	CcSEcCtD
Flurandrenolide—Hypersensitivity—Hydroxyurea—hematologic cancer	4.6e-05	0.00131	CcSEcCtD
Flurandrenolide—Rash—Imatinib—hematologic cancer	4.58e-05	0.0013	CcSEcCtD
Flurandrenolide—Dermatitis—Imatinib—hematologic cancer	4.57e-05	0.0013	CcSEcCtD
Flurandrenolide—Infection—Gemcitabine—hematologic cancer	4.54e-05	0.00129	CcSEcCtD
Flurandrenolide—Rash—Cladribine—hematologic cancer	4.5e-05	0.00128	CcSEcCtD
Flurandrenolide—Dermatitis—Cladribine—hematologic cancer	4.49e-05	0.00128	CcSEcCtD
Flurandrenolide—Pruritus—Lenalidomide—hematologic cancer	4.48e-05	0.00127	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—FOXO1—hematologic cancer	4.42e-05	0.00357	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—MAPK8—hematologic cancer	4.41e-05	0.00356	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—NCOR1—hematologic cancer	4.4e-05	0.00356	CbGpPWpGaD
Flurandrenolide—Budesonide—NR3C1—hematologic cancer	4.4e-05	0.0408	CrCbGaD
Flurandrenolide—Amcinonide—NR3C1—hematologic cancer	4.4e-05	0.0408	CrCbGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—STAT1—hematologic cancer	4.39e-05	0.00355	CbGpPWpGaD
Flurandrenolide—NR3C1—lymph node—hematologic cancer	4.35e-05	0.0355	CbGeAlD
Flurandrenolide—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—MAPK3—hematologic cancer	4.33e-05	0.0035	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Bortezomib—hematologic cancer	4.29e-05	0.00122	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—HDAC2—hematologic cancer	4.26e-05	0.00344	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Bleomycin—hematologic cancer	4.26e-05	0.00121	CcSEcCtD
Flurandrenolide—Infection—Cisplatin—hematologic cancer	4.23e-05	0.0012	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—HDAC2—hematologic cancer	4.22e-05	0.00341	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Vinorelbine—hematologic cancer	4.19e-05	0.00119	CcSEcCtD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—hematologic cancer	4.16e-05	0.00336	CbGpPWpGaD
Flurandrenolide—Rimexolone—NR3C1—hematologic cancer	4.14e-05	0.0384	CrCbGaD
Flurandrenolide—Pruritus—Bortezomib—hematologic cancer	4.12e-05	0.00117	CcSEcCtD
Flurandrenolide—Rash—Melphalan—hematologic cancer	4.1e-05	0.00117	CcSEcCtD
Flurandrenolide—Dermatitis—Melphalan—hematologic cancer	4.1e-05	0.00116	CcSEcCtD
Flurandrenolide—Pruritus—Bleomycin—hematologic cancer	4.09e-05	0.00116	CcSEcCtD
Flurandrenolide—Pruritus—Vinorelbine—hematologic cancer	4.02e-05	0.00114	CcSEcCtD
Flurandrenolide—Hypersensitivity—Thiotepa—hematologic cancer	4e-05	0.00114	CcSEcCtD
Flurandrenolide—Rash—Lenalidomide—hematologic cancer	3.99e-05	0.00113	CcSEcCtD
Flurandrenolide—Dermatitis—Lenalidomide—hematologic cancer	3.99e-05	0.00113	CcSEcCtD
Flurandrenolide—Rash—Hydroxyurea—hematologic cancer	3.93e-05	0.00112	CcSEcCtD
Flurandrenolide—Dermatitis—Hydroxyurea—hematologic cancer	3.93e-05	0.00112	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—HSP90AA1—hematologic cancer	3.92e-05	0.00317	CbGpPWpGaD
Flurandrenolide—Fluocinonide—NR3C1—hematologic cancer	3.9e-05	0.0362	CrCbGaD
Flurandrenolide—Infection—Etoposide—hematologic cancer	3.87e-05	0.0011	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—RUNX3—hematologic cancer	3.87e-05	0.00313	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Thalidomide—hematologic cancer	3.87e-05	0.0011	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—STAT5B—hematologic cancer	3.87e-05	0.00312	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—AR—hematologic cancer	3.86e-05	0.0358	CrCbGaD
Flurandrenolide—Pruritus—Thiotepa—hematologic cancer	3.84e-05	0.00109	CcSEcCtD
Flurandrenolide—Alclometasone—NR3C1—hematologic cancer	3.79e-05	0.0352	CrCbGaD
Flurandrenolide—Fluocinolone Acetonide—NR3C1—hematologic cancer	3.79e-05	0.0352	CrCbGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—STAT1—hematologic cancer	3.78e-05	0.00306	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—HDAC9—hematologic cancer	3.75e-05	0.00303	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—CREB1—hematologic cancer	3.72e-05	0.00301	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Carmustine—hematologic cancer	3.72e-05	0.00106	CcSEcCtD
Flurandrenolide—Pruritus—Thalidomide—hematologic cancer	3.71e-05	0.00106	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—FOXM1—hematologic cancer	3.71e-05	0.003	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AR—hematologic cancer	3.7e-05	0.00299	CbGpPWpGaD
Flurandrenolide—Flunisolide—NR3C1—hematologic cancer	3.69e-05	0.0343	CrCbGaD
Flurandrenolide—Fludrocortisone—NR3C1—hematologic cancer	3.69e-05	0.0343	CrCbGaD
Flurandrenolide—Hypersensitivity—Alitretinoin—hematologic cancer	3.68e-05	0.00105	CcSEcCtD
Flurandrenolide—NR3C1—Nuclear Receptor transcription pathway—ESR1—hematologic cancer	3.67e-05	0.00297	CbGpPWpGaD
Flurandrenolide—Rash—Bortezomib—hematologic cancer	3.67e-05	0.00104	CcSEcCtD
Flurandrenolide—Dermatitis—Bortezomib—hematologic cancer	3.67e-05	0.00104	CcSEcCtD
Flurandrenolide—Paramethasone—NR3C1—hematologic cancer	3.65e-05	0.0338	CrCbGaD
Flurandrenolide—Rash—Bleomycin—hematologic cancer	3.64e-05	0.00103	CcSEcCtD
Flurandrenolide—Dermatitis—Bleomycin—hematologic cancer	3.64e-05	0.00103	CcSEcCtD
Flurandrenolide—Hypersensitivity—Ifosfamide—hematologic cancer	3.64e-05	0.00103	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—MAPK14—hematologic cancer	3.63e-05	0.00293	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL10—hematologic cancer	3.63e-05	0.00293	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CSF2—hematologic cancer	3.59e-05	0.0029	CbGpPWpGaD
Flurandrenolide—Ciclesonide—NR3C1—hematologic cancer	3.59e-05	0.0333	CrCbGaD
Flurandrenolide—Rash—Vinorelbine—hematologic cancer	3.58e-05	0.00102	CcSEcCtD
Flurandrenolide—Dermatitis—Vinorelbine—hematologic cancer	3.58e-05	0.00102	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—MYB—hematologic cancer	3.57e-05	0.00289	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Vincristine—hematologic cancer	3.55e-05	0.00101	CcSEcCtD
Flurandrenolide—Pruritus—Alitretinoin—hematologic cancer	3.53e-05	0.001	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL4—hematologic cancer	3.53e-05	0.00285	CbGpPWpGaD
Flurandrenolide—Infection—Triamcinolone—hematologic cancer	3.51e-05	0.000998	CcSEcCtD
Flurandrenolide—Pruritus—Ifosfamide—hematologic cancer	3.49e-05	0.000992	CcSEcCtD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—TNF—hematologic cancer	3.49e-05	0.00282	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Irinotecan—hematologic cancer	3.45e-05	0.000981	CcSEcCtD
Flurandrenolide—Hypersensitivity—Mitoxantrone—hematologic cancer	3.45e-05	0.000981	CcSEcCtD
Flurandrenolide—Methylprednisolone—NR3C1—hematologic cancer	3.44e-05	0.0319	CrCbGaD
Flurandrenolide—Rash—Thiotepa—hematologic cancer	3.42e-05	0.000972	CcSEcCtD
Flurandrenolide—Dermatitis—Thiotepa—hematologic cancer	3.42e-05	0.000971	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—hematologic cancer	3.41e-05	0.00275	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—STAT5A—hematologic cancer	3.4e-05	0.00275	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALB—hematologic cancer	3.39e-05	0.00274	CbGpPWpGaD
Flurandrenolide—Rash—Thalidomide—hematologic cancer	3.31e-05	0.00094	CcSEcCtD
Flurandrenolide—Dermatitis—Thalidomide—hematologic cancer	3.31e-05	0.00094	CcSEcCtD
Flurandrenolide—Pruritus—Gemcitabine—hematologic cancer	3.23e-05	0.000918	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—IL10—hematologic cancer	3.23e-05	0.00261	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—hematologic cancer	3.23e-05	0.00261	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—HLA-A—hematologic cancer	3.2e-05	0.00258	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—GATA3—hematologic cancer	3.19e-05	0.00258	CbGpPWpGaD
Flurandrenolide—Infection—Betamethasone—hematologic cancer	3.19e-05	0.000906	CcSEcCtD
Flurandrenolide—Infection—Dexamethasone—hematologic cancer	3.19e-05	0.000906	CcSEcCtD
Flurandrenolide—Rash—Carmustine—hematologic cancer	3.18e-05	0.000903	CcSEcCtD
Flurandrenolide—Dermatitis—Carmustine—hematologic cancer	3.18e-05	0.000902	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CSF2—hematologic cancer	3.16e-05	0.00256	CbGpPWpGaD
Flurandrenolide—Rash—Alitretinoin—hematologic cancer	3.15e-05	0.000895	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO1—hematologic cancer	3.15e-05	0.00254	CbGpPWpGaD
Flurandrenolide—Dermatitis—Alitretinoin—hematologic cancer	3.15e-05	0.000894	CcSEcCtD
Flurandrenolide—Hypersensitivity—Cisplatin—hematologic cancer	3.14e-05	0.000891	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—CREBBP—hematologic cancer	3.12e-05	0.00252	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—BAX—hematologic cancer	3.12e-05	0.00252	CbGpPWpGaD
Flurandrenolide—Rash—Ifosfamide—hematologic cancer	3.11e-05	0.000884	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—CREB1—hematologic cancer	3.11e-05	0.00251	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL4—hematologic cancer	3.11e-05	0.00251	CbGpPWpGaD
Flurandrenolide—Dermatitis—Ifosfamide—hematologic cancer	3.11e-05	0.000883	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL13—hematologic cancer	3.06e-05	0.00247	CbGpPWpGaD
Flurandrenolide—Rash—Vincristine—hematologic cancer	3.03e-05	0.000862	CcSEcCtD
Flurandrenolide—Dermatitis—Vincristine—hematologic cancer	3.03e-05	0.000861	CcSEcCtD
Flurandrenolide—NR3C1—Circadian Clock—CREBBP—hematologic cancer	3.03e-05	0.00245	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—ESR1—hematologic cancer	2.97e-05	0.0276	CrCbGaD
Flurandrenolide—Rash—Mitoxantrone—hematologic cancer	2.96e-05	0.00084	CcSEcCtD
Flurandrenolide—Rash—Irinotecan—hematologic cancer	2.96e-05	0.00084	CcSEcCtD
Flurandrenolide—Dermatitis—Mitoxantrone—hematologic cancer	2.95e-05	0.000839	CcSEcCtD
Flurandrenolide—Dermatitis—Irinotecan—hematologic cancer	2.95e-05	0.000839	CcSEcCtD
Flurandrenolide—Rash—Gemcitabine—hematologic cancer	2.88e-05	0.000818	CcSEcCtD
Flurandrenolide—Dermatitis—Gemcitabine—hematologic cancer	2.88e-05	0.000817	CcSEcCtD
Flurandrenolide—Hypersensitivity—Etoposide—hematologic cancer	2.87e-05	0.000816	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—ESR1—hematologic cancer	2.85e-05	0.0023	CbGpPWpGaD
Flurandrenolide—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—hematologic cancer	2.83e-05	0.00229	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Prednisolone—hematologic cancer	2.83e-05	0.000805	CcSEcCtD
Flurandrenolide—NR3C1—Endoderm Differentiation—NOTCH1—hematologic cancer	2.82e-05	0.00228	CbGpPWpGaD
Flurandrenolide—NR3C1—Transcription factor regulation in adipogenesis—IL6—hematologic cancer	2.81e-05	0.00227	CbGpPWpGaD
Flurandrenolide—Infection—Prednisone—hematologic cancer	2.78e-05	0.000789	CcSEcCtD
Flurandrenolide—Pruritus—Etoposide—hematologic cancer	2.76e-05	0.000784	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—GATA3—hematologic cancer	2.76e-05	0.00223	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK2—hematologic cancer	2.7e-05	0.00218	CbGpPWpGaD
Flurandrenolide—Rash—Cisplatin—hematologic cancer	2.68e-05	0.000762	CcSEcCtD
Flurandrenolide—Dermatitis—Cisplatin—hematologic cancer	2.68e-05	0.000762	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—MDM2—hematologic cancer	2.65e-05	0.00214	CbGpPWpGaD
Flurandrenolide—Medroxyprogesterone Acetate—NR3C1—hematologic cancer	2.62e-05	0.0243	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—STAT1—hematologic cancer	2.62e-05	0.00211	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Triamcinolone—hematologic cancer	2.61e-05	0.00074	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—FOS—hematologic cancer	2.57e-05	0.00208	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CREB1—hematologic cancer	2.57e-05	0.00207	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—MAPK14—hematologic cancer	2.56e-05	0.00207	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—hematologic cancer	2.55e-05	0.00206	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—ESR1—hematologic cancer	2.54e-05	0.00205	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CCL2—hematologic cancer	2.51e-05	0.00203	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ZNF552—hematologic cancer	2.5e-05	0.00202	CbGpPWpGaD
Flurandrenolide—Pruritus—Triamcinolone—hematologic cancer	2.5e-05	0.000711	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—ICAM1—hematologic cancer	2.47e-05	0.002	CbGpPWpGaD
Flurandrenolide—Rash—Etoposide—hematologic cancer	2.46e-05	0.000698	CcSEcCtD
Flurandrenolide—Dermatitis—Etoposide—hematologic cancer	2.46e-05	0.000698	CcSEcCtD
Flurandrenolide—Prednisolone—NR3C1—hematologic cancer	2.43e-05	0.0225	CrCbGaD
Flurandrenolide—Rash—Prednisolone—hematologic cancer	2.42e-05	0.000689	CcSEcCtD
Flurandrenolide—Dermatitis—Prednisolone—hematologic cancer	2.42e-05	0.000688	CcSEcCtD
Flurandrenolide—Betamethasone—NR3C1—hematologic cancer	2.38e-05	0.022	CrCbGaD
Flurandrenolide—NR3C1—Adipogenesis—STAT5A—hematologic cancer	2.35e-05	0.0019	CbGpPWpGaD
Flurandrenolide—Infection—Methotrexate—hematologic cancer	2.32e-05	0.000659	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—JUN—hematologic cancer	2.31e-05	0.00186	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOS—hematologic cancer	2.29e-05	0.00185	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREB1—hematologic cancer	2.28e-05	0.00184	CbGpPWpGaD
Flurandrenolide—Pruritus—Betamethasone—hematologic cancer	2.27e-05	0.000645	CcSEcCtD
Flurandrenolide—Pruritus—Dexamethasone—hematologic cancer	2.27e-05	0.000645	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—FOS—hematologic cancer	2.26e-05	0.00183	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CREB1—hematologic cancer	2.26e-05	0.00183	CbGpPWpGaD
Flurandrenolide—Rash—Triamcinolone—hematologic cancer	2.23e-05	0.000633	CcSEcCtD
Flurandrenolide—Dermatitis—Triamcinolone—hematologic cancer	2.23e-05	0.000633	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—hematologic cancer	2.22e-05	0.0018	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—NCOR1—hematologic cancer	2.21e-05	0.00179	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—hematologic cancer	2.2e-05	0.00178	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CDKN2A—hematologic cancer	2.19e-05	0.00177	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—AR—hematologic cancer	2.19e-05	0.00177	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—MAPK8—hematologic cancer	2.18e-05	0.00176	CbGpPWpGaD
Flurandrenolide—Infection—Epirubicin—hematologic cancer	2.17e-05	0.000617	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—FOXO1—hematologic cancer	2.16e-05	0.00174	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—ABCG2—hematologic cancer	2.15e-05	0.0199	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IFNG—hematologic cancer	2.13e-05	0.00172	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—EP300—hematologic cancer	2.13e-05	0.00172	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—RARA—hematologic cancer	2.07e-05	0.00167	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of Androgen receptor activity—SRC—hematologic cancer	2.07e-05	0.00167	CbGpPWpGaD
Flurandrenolide—NR3C1—Circadian Clock—EP300—hematologic cancer	2.06e-05	0.00167	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Prednisone—hematologic cancer	2.06e-05	0.000585	CcSEcCtD
Flurandrenolide—Rash—Betamethasone—hematologic cancer	2.02e-05	0.000575	CcSEcCtD
Flurandrenolide—Rash—Dexamethasone—hematologic cancer	2.02e-05	0.000575	CcSEcCtD
Flurandrenolide—Dermatitis—Betamethasone—hematologic cancer	2.02e-05	0.000574	CcSEcCtD
Flurandrenolide—Dermatitis—Dexamethasone—hematologic cancer	2.02e-05	0.000574	CcSEcCtD
Flurandrenolide—Infection—Doxorubicin—hematologic cancer	2.01e-05	0.000571	CcSEcCtD
Flurandrenolide—NR3C1—Adipogenesis—FAS—hematologic cancer	1.98e-05	0.0016	CbGpPWpGaD
Flurandrenolide—Pruritus—Prednisone—hematologic cancer	1.98e-05	0.000562	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CDKN1B—hematologic cancer	1.94e-05	0.00157	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NR0B2—hematologic cancer	1.92e-05	0.00155	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—HES1—hematologic cancer	1.92e-05	0.00155	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL10—hematologic cancer	1.91e-05	0.00154	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL2—hematologic cancer	1.9e-05	0.00153	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—CASC3—hematologic cancer	1.9e-05	0.00153	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IFNG—hematologic cancer	1.88e-05	0.00152	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—MDM2—hematologic cancer	1.87e-05	0.00151	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—NR3C1—hematologic cancer	1.86e-05	0.0172	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—CCND1—hematologic cancer	1.85e-05	0.00149	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—JUN—hematologic cancer	1.85e-05	0.00149	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—PTEN—hematologic cancer	1.78e-05	0.00144	CbGpPWpGaD
Flurandrenolide—Rash—Prednisone—hematologic cancer	1.76e-05	0.000501	CcSEcCtD
Flurandrenolide—Dermatitis—Prednisone—hematologic cancer	1.76e-05	0.0005	CcSEcCtD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NCOR2—hematologic cancer	1.74e-05	0.0014	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Methotrexate—hematologic cancer	1.72e-05	0.000489	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—EP300—hematologic cancer	1.7e-05	0.00138	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL2—hematologic cancer	1.67e-05	0.00135	CbGpPWpGaD
Flurandrenolide—Methylprednisolone—ABCB1—hematologic cancer	1.66e-05	0.0154	CrCbGaD
Flurandrenolide—Pruritus—Methotrexate—hematologic cancer	1.65e-05	0.000469	CcSEcCtD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—JUN—hematologic cancer	1.64e-05	0.00133	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—JUN—hematologic cancer	1.63e-05	0.00131	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Epirubicin—hematologic cancer	1.61e-05	0.000457	CcSEcCtD
Flurandrenolide—Dexamethasone—ABCG2—hematologic cancer	1.6e-05	0.0149	CrCbGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—hematologic cancer	1.59e-05	0.00129	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—hematologic cancer	1.58e-05	0.00127	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—CREB1—hematologic cancer	1.56e-05	0.00126	CbGpPWpGaD
Flurandrenolide—Pruritus—Epirubicin—hematologic cancer	1.55e-05	0.000439	CcSEcCtD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—MAPK8—hematologic cancer	1.54e-05	0.00124	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—RB1—hematologic cancer	1.52e-05	0.00123	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—hematologic cancer	1.51e-05	0.00122	CbGpPWpGaD
Flurandrenolide—NR3C1—Endoderm Differentiation—TGFB1—hematologic cancer	1.51e-05	0.00122	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—EP300—hematologic cancer	1.5e-05	0.00121	CbGpPWpGaD
Flurandrenolide—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—hematologic cancer	1.49e-05	0.0012	CbGpPWpGaD
Flurandrenolide—Hypersensitivity—Doxorubicin—hematologic cancer	1.49e-05	0.000423	CcSEcCtD
Flurandrenolide—NR3C1—AP-1 transcription factor network—MYC—hematologic cancer	1.48e-05	0.0012	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—TGFB1—hematologic cancer	1.48e-05	0.0012	CbGpPWpGaD
Flurandrenolide—Rash—Methotrexate—hematologic cancer	1.47e-05	0.000418	CcSEcCtD
Flurandrenolide—Dermatitis—Methotrexate—hematologic cancer	1.47e-05	0.000418	CcSEcCtD
Flurandrenolide—Pruritus—Doxorubicin—hematologic cancer	1.43e-05	0.000406	CcSEcCtD
Flurandrenolide—Dexamethasone—NR3C1—hematologic cancer	1.38e-05	0.0128	CrCbGaD
Flurandrenolide—Rash—Epirubicin—hematologic cancer	1.38e-05	0.000391	CcSEcCtD
Flurandrenolide—Dermatitis—Epirubicin—hematologic cancer	1.38e-05	0.000391	CcSEcCtD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CREB1—hematologic cancer	1.35e-05	0.00109	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—MAPK3—hematologic cancer	1.34e-05	0.00109	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—hematologic cancer	1.32e-05	0.00107	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL6R—hematologic cancer	1.32e-05	0.00107	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CREBBP—hematologic cancer	1.32e-05	0.00106	CbGpPWpGaD
Flurandrenolide—Rash—Doxorubicin—hematologic cancer	1.28e-05	0.000362	CcSEcCtD
Flurandrenolide—Dermatitis—Doxorubicin—hematologic cancer	1.27e-05	0.000362	CcSEcCtD
Flurandrenolide—NR3C1—Gene Expression—RARS—hematologic cancer	1.22e-05	0.000987	CbGpPWpGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—TP53—hematologic cancer	1.22e-05	0.000984	CbGpPWpGaD
Flurandrenolide—Prednisolone—ABCB1—hematologic cancer	1.17e-05	0.0109	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—POLR3E—hematologic cancer	1.15e-05	0.000928	CbGpPWpGaD
Flurandrenolide—Betamethasone—ABCB1—hematologic cancer	1.15e-05	0.0106	CrCbGaD
Flurandrenolide—NR3C1—AP-1 transcription factor network—IL6—hematologic cancer	1.11e-05	0.000901	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—PARP1—hematologic cancer	1.1e-05	0.000893	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—CDKN1A—hematologic cancer	1.09e-05	0.000881	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—TP53—hematologic cancer	1.07e-05	0.000867	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL1B—hematologic cancer	1e-05	0.00081	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—CASP3—hematologic cancer	1e-05	0.000808	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RARA—hematologic cancer	9.96e-06	0.000805	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—TET2—hematologic cancer	9.96e-06	0.000805	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—IL6—hematologic cancer	9.82e-06	0.000794	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPLP1—hematologic cancer	9.77e-06	0.000789	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—STAT3—hematologic cancer	9.73e-06	0.000786	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—JUN—hematologic cancer	9.72e-06	0.000785	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NR0B2—hematologic cancer	9.26e-06	0.000748	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—AR—hematologic cancer	9.24e-06	0.000747	CbGpPWpGaD
Flurandrenolide—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—hematologic cancer	9.15e-06	0.000739	CbGpPWpGaD
Flurandrenolide—NR3C1—Glucocorticoid receptor regulatory network—AKT1—hematologic cancer	9.06e-06	0.000732	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—TGFB1—hematologic cancer	9.02e-06	0.000729	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—EP300—hematologic cancer	8.96e-06	0.000724	CbGpPWpGaD
Flurandrenolide—Hydrocortisone—ABCB1—hematologic cancer	8.95e-06	0.0083	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—DNMT3A—hematologic cancer	8.83e-06	0.000714	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ELL—hematologic cancer	8.71e-06	0.000703	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—CDKN2B—hematologic cancer	8.52e-06	0.000688	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—VEGFA—hematologic cancer	8.49e-06	0.000686	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—TNF—hematologic cancer	8.42e-06	0.00068	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NCOR2—hematologic cancer	8.36e-06	0.000675	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NCOR1—hematologic cancer	8.08e-06	0.000653	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—AGO2—hematologic cancer	7.71e-06	0.000623	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—DNMT3B—hematologic cancer	7.55e-06	0.00061	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—H3F3B—hematologic cancer	7.55e-06	0.00061	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—TNF—hematologic cancer	7.28e-06	0.000588	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—RPS14—hematologic cancer	6.9e-06	0.000558	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NUP98—hematologic cancer	6.8e-06	0.000549	CbGpPWpGaD
Flurandrenolide—NR3C1—Adipogenesis—IL6—hematologic cancer	6.79e-06	0.000549	CbGpPWpGaD
Flurandrenolide—Dexamethasone—ABCB1—hematologic cancer	6.67e-06	0.00619	CrCbGaD
Flurandrenolide—NR3C1—Gene Expression—NUP214—hematologic cancer	6.55e-06	0.000529	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—ESR1—hematologic cancer	6.35e-06	0.000513	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—NOTCH1—hematologic cancer	6.13e-06	0.000496	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—HSPB1—hematologic cancer	6.04e-06	0.000488	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—EIF4EBP1—hematologic cancer	6.04e-06	0.000488	CbGpPWpGaD
Flurandrenolide—NR3C1—SIDS Susceptibility Pathways—IL6—hematologic cancer	5.87e-06	0.000474	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—SMC1A—hematologic cancer	5.78e-06	0.000467	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—H3F3A—hematologic cancer	5.67e-06	0.000458	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—CREBBP—hematologic cancer	5.56e-06	0.000449	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—EZH2—hematologic cancer	5.43e-06	0.000439	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—PARP1—hematologic cancer	5.32e-06	0.00043	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—HDAC2—hematologic cancer	5.13e-06	0.000415	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—AR—hematologic cancer	4.45e-06	0.000359	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—CDKN2B—hematologic cancer	4.1e-06	0.000331	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NCOR1—hematologic cancer	3.89e-06	0.000314	CbGpPWpGaD
Flurandrenolide—NR3C1—Generic Transcription Pathway—MYC—hematologic cancer	3.3e-06	0.000267	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MAPK14—hematologic cancer	3.11e-06	0.000252	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—ESR1—hematologic cancer	3.05e-06	0.000247	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—NOTCH1—hematologic cancer	2.95e-06	0.000239	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—CREBBP—hematologic cancer	2.68e-06	0.000216	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MAPK3—hematologic cancer	1.63e-06	0.000132	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—MYC—hematologic cancer	1.59e-06	0.000128	CbGpPWpGaD
Flurandrenolide—NR3C1—Gene Expression—AKT1—hematologic cancer	1.1e-06	8.9e-05	CbGpPWpGaD
